Kornimate/medical-research-clean huggingface dataset:
patient and physician survey determinants of appropriate icd utilization

Conditions: Heart Failure, Systolic

Summary: to better understand the reasons for underutilization of defibrillator therapy in selected populations, the investigators propose a study to assess heart failure patient knowledge and attitudes toward device therapy. by carefully studying populations of patients with systolic heart failure, the investigators aim to identify the underlying reasons for implantable cardioverter defibrillators (icd) non-utilization in patients with symptomatic systolic heart failure.

several multi-center randomized trials have demonstrated the benefit of implantable cardioverter defibrillators (icds) for the primary prevention of sudden cardiac death among patients with ischemic and nonischemic cardiomyopathy. guideline documents for the treatment of heart failure have recommended defibrillator placement for patients with symptomatic heart failure and left ventricular ejection fraction (lvef) ≤ 35%. despite these recommendations, observational studies have documented low icd utilization among patients with heart failure. recent studies have demonstrated patient specific characteristics that are associated with low icd utilization (advanced age, female gender, black race, heart failure etiology, uninsured patients and patients cared for by general practitioners). whether patient knowledge or attitudes regarding defibrillator therapy influence the rate of defibrillator placement is unknown. by carefully surveying populations of patients with systolic heart failure, we aim to further the understanding of the patient factors that determine why an icd may or may not be used in the appropriate clinical setting. additionally, 150 physicians will be enrolled into the study for the purpose of measuring attitudes and beliefs regarding defibrillator treatment for the physicians providing care to the patients in the study.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * left ventricular ejection fraction ≤ 35% * previous diagnosis of heart failure with current nyha class ii-iii symptoms * established umhs patient with at least two outpatient visits in the past two years to either primary care or cardiology, or, at least one inpatient admission in the past two years along with at least one outpatient visit within the past 13 months to primary care or cardiology exclusion criteria: * patients having undergone heart transplantation * patients having undergone placement of a left ventricular assist device * patients with congenital heart disease

Keywords: left ventricular systolic dysfunction implantable cardioverter defibrillator systolic heart failure congestive heart failure ischemic cardiomyopathy nonischemic cardiomyopathy icd icd utilization icd implantation defibrillator defibrillator therapy sudden cardiac death
optimal management of urinary catheter in gyn onc

Conditions: Urinary Retention

Summary: this is a combined retrospective observational study that will collect data on urinary catheter removal of patients who underwent pelvic surgery by a gynecologic oncologist to assess timing safety and its implications in postoperative care.


Eligibility criteria:
inclusion criteria: * age above 18 * female gender * undergoing pelvic surgery for benign or malignant indications by a gynecologic oncologist exclusion criteria: * age less than 18 years of age at the time of surgery * pregnant * individual is a prisoner

Keywords: urinary retention postoperative urinary complications pelvic surgery hysterectomy gynecologic oncology
assessing patient-reported experience of care for home dialysis (aspired)

Conditions: Home Dialysis; End Stage Renal Disease

Summary: home dialysis modalities, including peritoneal dialysis (pd) and home hemodialysis (hhd), represent alternatives to conventional in-center hemodialysis (hd) that for some patients may be better aligned with preferences regarding the integration of dialysis treatments into their lives. assessment of patient experience and satisfaction with care among individuals undergoing maintenance dialysis in the united states is a national health care priority and mandated by congress. while validated instruments (ich cahps) are in use to assess patient experience with in-center hd, currently no validated instruments are available to measure patient-reported experience in home dialysis. this home patient experience survey validation study is an in-house research study conducted in partnership with the university of washington.

assessment of patient experience and satisfaction with care among individuals undergoing maintenance dialysis in the united states is a national health care priority and mandated by congress. no validated instruments are available to measure the patient-reported experience of care in-home dialysis patients. such tools are needed as more patients are expected to choose home dialysis therapies in the future. this study aims to validate a home patient experience survey instrument. this is a cross-sectional validation to determine the measurement properties of a new home dialysis patient experience survey instrument. satellite healthcare home dialysis patients will be approached by mail or by phone to complete the survey. the aim of this study is to perform field testing for this newly developed instrument for the purposes of instrument validation and to determine survey instrument measurement properties. this will include the evaluation of any multi-item scales as well as an overall score.

Eligibility criteria:
inclusion criteria: * patients receiving care for home dialysis at a facility that provides care for \>= 3 patients at the time of cohort identification. exclusion criteria: * age \< 18 years * patients receiving care for home dialysis at the facility for less than 3 months * institutionalized (senior nursing facility/multi-resident facility) or hospice care patients

Keywords: esrd dialysis patient experience home dialysis
angiotensin converting enzyme rs (1799752) gene polymorphism and development of in-stent restenosis in patients with stable coronary artery diseases in sohag hospital university.

Conditions: Angiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery Diseases

Summary: one of the most common medical approaches to the treatment of coronary artery disease (cad) is the percutaneous coronary intervention (pci) which became frequent due to high efﬁciency and safety of this procedure. modern-day advances in pharmacotherapy and the device innovations over the last thirty years enhanced the benign outcomes of patients with unstable or multivessel cad, and multiple co-morbidities, treated by pci . in-stent restenosis (isr) is a recognized complication following percutaneous coronary intervention in which the luminal diameter is narrowed through neointimal hyperplasia and vessel remodeling. although rates of isr have decreased in most recent years owing to newer generation drug-eluting stents, thinner struts, and better intravascular imaging modalities, isr remains a prevalent dilemma that proves to be challenging to manage. several factors have been proposed to contribute to isr formation, including mechanical stent characteristics, technical factors during the coronary intervention, and biological aspects of drug-eluting stents .identiﬁcation of risk factors and mechanisms underlying isr is necessary for understanding the process, the risk stratiﬁcation, and optimal treatment development. restenosis, as a physiological response to mechanical damage, involves two mechanisms which are neointimal hyperplasia and vessel remodeling \[3\]. several factors such as age, diabetes mellitus, hypertension, stenting of small coronary arteries, and ﬁnal total length of stents have been shown to be associated with an elevated risk of restenosis.


Eligibility criteria:
inclusion criteria: * patients with cad exclusion criteria: * patients without other health problems
study of tq-f3083 capsules in subjects with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: tq-f3083 capsule is a new type inhibitor of dpp-iv, which is currently a very effective target for the treatment of type 2 diabetes mellitus at clinical. in addition, it can promote insulin secretion with low potential toxicity, and half-life is shorter than linagliptin.


Eligibility criteria:
inclusion criteria: 1.understood and signed an informed consent form; 2.18 and 70 years old; 3.body mass index (bmi) of 19 to 37.5 kg/m2; 4.type 2 diabetes mellitus confirmed at least 6 weeks before screen by who (1999) diabetes mellitus diagnostic criteria; 5.has inadequate glycemic control on diet/exercise therapy and irregular use hypoglycemic agents before screening, hba1c ≥7.0% and ≤10.0% ; has regular hypoglycemic agents with stable dose within 6 weeks before screening, hba1c ≥7.0% and ≤9 %; 6.pfg ≤ 13.3 mmol / l; 7. adequate laboratory inspection standards. exclusion criteria: 1. has any contraindications, allergies or hypersensitivity for taking research medication ; 2. has used at lest two oral medications to treat diabetes mellitus 6 weeks before screening; 3. has other endocrine-related history or evidence before screening; 4. has history of organ transplantation; 5. has mental or neurological diseases; 6. has received systemic corticosteroids within 2 weeks; 7. has received glp-1 analogues, dpp-4 inhibitors or anti-obesity drugs 3 months ; 8. has alcohol abuse history within 6 months before screening; 9. has participated in any clinical trial within 3 months; 10. has received blood transfusions, or blood donation ≥ 400 ml , or got severe blood loss ≥ 400 ml within 8 weeks; 11. pregnant or lactating woman.
a case-control study on the clinical characteristics of 28-day and 90-day death from severe anthrax

Conditions: Anthrax

Summary: this study is a clinical, multi-center, retrospective, case-control study. patients clinically diagnosed with severe anthrax who meet the inclusion and exclusion criteria will be included in this study for analysis. respiratory, circulation, nerve and other vital signs of patients with severe anthrax during hospitalization were recorded, and clinical data such as blood routine, blood biochemistry, coagulation function, myocardial injury, therapeutic drug use, and survival time of patients were recorded, as well as the survival situation of patients 28 days and 90 days after discharge.


Eligibility criteria:
inclusion criteria: 1. the typical bacilli with capsules were found in smear examination and culture of various secretions, excretions, blood and cerebrospinal fluid. 2. multiple organ dysfunction (mods) in brain, heart, liver, kidney, coagulation or more than one organ failure. exclusion criteria: there are other conditions that affect short-term survival.
sucrose practices for pain in neonates

Conditions: Pain

Summary: recent studies show that babies in hospital undergo an average of 4 to 5 painful procedures, such as heel lances, every day. sucrose (sugar water) has been shown to be effective for reducing pain during invasive procedures and is a standard of care for painful procedures. the purpose of this study is to see what is the least amount of sucrose that can be given to a baby to reduce pain during procedures.

infants in the nicu receive an average of 4 - 5 painful procedures daily for diagnostic and therapeutic purposes; less than half receive interventions to manage pain. both immediate and long term effects of unmanaged pain in these vulnerable infants have been reported, including impaired brain development. to ensure optimal outcomes for hospitalized infants in nicus, there is a crucial need to minimize procedural pain and its associated consequences. multiple clinical trials have identified sucrose as an effective strategy for reducing procedural pain in infants. despite its inclusion in neonatal pain guidelines, standards, and consensus statements sucrose has been inconsistently used. the under-utilization of sucrose may be explained by knowledge gaps in relation to the minimally effective dose and the influence of concurrent opioid analgesia, as well as the short and long-term effects of repeated administration. once infants in the nicu are determined to be eligible for the study and parents consent, infants will be randomized to one of 3 dose of sucrose and their pain will be assessed using a validated pain assessment measure.

Eligibility criteria:
inclusion criteria: * infants 24 to 42 weeks gestational age (ga) at birth, admitted to the neonatal intensive care unit (nicu), and scheduled to receive a heel lance will be eligible. parents will be approached for participation within the first 2 weeks of the infant's life. infants will be eligible for trial 1, the non-opioid trial, if they have not received any opioids within 24 hours prior to the heel lance. infants will be eligible for trial 2, the opioid trial, if they are currently receiving an opioid infusion. furthermore, observation of the procedures will be timed to ensure that no additional sucrose doses are provided within the previous 4 hours. exclusion criteria: * infants will be excluded if they have a contraindication for sucrose administration (e.g., unable to swallow, pharmacologically muscle relaxed, or heavily sedated) due to safety concerns and/or inability to assess pain accurately (e.g., unable to clearly view the infant's face).

Keywords: pain pain management hospitalized infants sucrose
study of the hematopoietic niche and the role of inflammation in the pathophysiology of cytopenias after car-t cell therapy: potential of therapies directed to repair the bone marrow microenvironment

Conditions: Diffuse Large B Cell Lymphoma

Summary: immunotherapy with chimeric antigen receptor t-cells (car-t) has revolutionized the treatment of oncohematological diseases and its applications in solid tumors and non-neoplastic diseases are advancing. cytopenias after car-t therapy are the most frequent complication in the medium and long term after treatment, they are a cause of morbimortality, and there are no effective therapies available. the general objective of the present research project is to analyze, in a series of 40 patients with diffuse large b-cell lymphoma undergoing consecutive commercial car-t therapy at the university hospital of salamanca, the characteristics of the hematopoietic niche and the systemic and bone marrow inflammatory status in patients with prolonged cytopenias after car-t cell therapy with respect to those without cytopenias and with respect to the pre-treatment situation (performing quantitative and functional analysis of the stroma by immunohistochemistry, flow cytometry and genomic studies, in addition to functional hematopoietic assays-clonogenic assays, long-term cultures-), and to evaluate both in vitro (by co-culturing with macrophages activated by car-t/tumor cell interaction and assessing cytokines) and in vivo (in an animal model of lymphoma and crs) the therapeutic potential of therapies aimed at repairing the hematopoietic bone marrow microenvironment, such as the use of allogeneic mesenchymal cells (msc) from healthy donors and msc-derived extracellular vesicles (msc-ev) studying their effects on inflammatory mediators, hematopoiesis and the cytotoxic effect of car-t.


Eligibility criteria:
inclusion criteria: * patients with diffuse large b-cell lymphoma undergoing consecutive commercial car-t therapy * over 18 years old * sign the informed consent exclusion criteria: * under 18 years old * do not sign the informed consent

Keywords: lymphoma b cell car-t therapy cytopenia hematopoietic niche inflammation
energy specific far infrared radiation treatment for hyperparathyroidism

Conditions: Hyperparathyroidism

Summary: a study to determine the possibility of using far infrared radiation to treat hyperparathyroidism.

overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones. we are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.

Eligibility criteria:
inclusion criteria: * persons with parathyroid disease exclusion criteria: * none

Keywords: primary hyperparathyroidism parathyroid neoplasms secondary hyperparathyroidism hypocalcemia
tissue distribution of f18-fdg labelled autologous bone marrow derived stem cells in patients with type 2 dm

Conditions: Type 2 Diabetes Mellitus

Summary: investigators purpose is to track stem cells in vivo in the type 2 diabetes mellitus patients after the same have been labelled with positron emission tomography tracer f18-fdg; as it is assumed that the therapeutic outcome will profoundly depend on the delivery of these cells to pancreas. biodistribution and quantification studies will be done at 30 minutes and 90 minutes of stem cell infusion.

autologous bone marrow derived stem cells have a promising potential in regenerative medicine. in particular the past decade has garnered a great interest in cellular therapy for treating type2 diabetes mellitus. the pertinent questions in regenerative medicine today are to know about the homing, survival, differentiation and functionality of the cells and based on these to find out the adequate administration methods and choose the optimal dose and cell types. various modalities have been used in the preclinical and clinical trials. these include mri,optical imaging in the form of bioluminescence and fluorescence, quantum dots, spect and pet/ct imaging. however the methods which are suitable for stem cell tracking in small animals are not easily translated for human trials. in humans pet/ct imaging with its reasonable resolution and unique ability to combine anatomical and functional imaging is considered to be the best bet yet. hence we intend to label the autologous bone marrow derived stem cells with pet tracer f18-fdg and carry out biodistribution studies, our ultimate aim being to study how in vivo distribution of the cells affect therapeutic efficacy.

Eligibility criteria:
inclusion criteria: * patients with t2dm between 30 and 70 years of age. * failure to triple oha and on stable doses of insulin for at least 3 months. * on vildagliptin, pioglitazone and metformin for at least 3 months along with insulin to maintain euglycemia. * hba1c of 6.5-7.5% * insulin requirement ≥0.4 iu/kg/d. * glutamic acid decarboxylase (gad 65) antibody negative status. exclusion criteria: * patients with t1dm or secondary diabetes. * patients with serum creatinine \> 1.5 mg/dl. * abnormal liver function tests (defined as value of transaminases \> 3 times the upper value of normal or serum bilirubin higher than normal for the reference value for the laboratory). * history of pancreatitis * seropositivity for hiv, hbsag and hcv. * history of myocardial infarction or unstable angina in the previous 3 months. * history of malignancy * patients with active infections. * female patients who are pregnant or lactating

Keywords: type 2 diabetes mellitus, f18-fdg labelled stem cells
superno2va et versus oxygen face mask during deep sedation

Conditions: Hypoxemia

Summary: the primary objective of the study is to prospectively and randomly compare the incidence, duration, and severity of oxygen desaturation between a nasal mask with nasal positive airway pressure (pap) versus oxygen therapy with a facemask during procedural deep sedation in patients considered high risk for hypoxia (ie: bmi ≥30 kg/m2 or documented obstructive sleep apnea.


Eligibility criteria:
inclusion criteria: 1. age 18 years of age or older 2. patients undergoing procedural deep sedation 3. american society of anesthesiology (asa) physical status i-iii 4. bmi ≥30 kg/m2 or documented obstructive sleep apnea 5. has provided written informed consent 6. difficult airway exclusion criteria: 1. acute exacerbation of respiratory disorders, including copd and asthma 2. emergent procedures 3. pregnancy 4. previous enrollment in this study 5. inability to provide informed consent 6. history of allergic reaction to propofol 7. tracheostomy 8. exclusion criteria: deep sedation procedures that require intra-oral instrumentation (ie: egd, transesophageal echocardiography

Keywords: oxygenation hypoxemia deep sedation end-tidal co2 continuous positive airway pressure
dose ranging study of rpc4046 in eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: the purpose of this study is to determine the effective dose(s) of rpc4046 in the treatment of eosinophilic esophagitis (eoe). this trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.


Eligibility criteria:
inclusion criteria: * histologic evidence of eoe * clinical symptoms of eoe including dysphagia exclusion criteria: * primary causes of esophageal eosinophilia other than eoe
geriatric assessment and intervention in older patients undergoing surgery for colorectal cancer

Conditions: Colon Cancer; Colon Neoplasm; Frail Elderly Syndrome; Colorectal Cancer

Summary: the gepoc study investigates the effect of comprehensive geriatric assessment and intervention for frail older patients (65 years or older) undergoing elective surgery for colorectal cancer. the geriatric intervention will be pre- and postoperative. included in the intervention is an exercise intervention. the main aim of the study us to see if the functional decline in this group can be reduced.

this is a randomized, controlled trial on frail older patients (aged 65 years or older) with colorectal cancer. the patients will be randomized into two groups. the control group will receive standard surgical treatment. the intervention group will in addition go through a preoperative comprehensive geriatric assessment. the assessment will include evaluation of co-morbidity and medication, social status, nutritional status, cognition, depression and physical performance. this assessment will form basis of an individualized intervention. patients in the intervention group will participate in planned exercise programs before surgery, perioperative and postoperative.

Eligibility criteria:
inclusion criteria: * elective surgery for colorectal cancer * frail * ability to read and speak danish (informed concent) exclusion criteria: * any physical condition that hinder physical exercise (eg. no legs) * not able to concent

Keywords: colon cancer frailty geriatric assessment perioperative care exercise quality of recovery colorectal